BioLineRx, Israel’s Biotech Incubator, Nearing Major Inflection Points
This article was originally published in The Pink Sheet Daily
Executive Summary
Funded in part by the Israeli government, BioLineRx believes it is about to score big with a cardiology drug being developed under FDA’s regulatory pathway for devices, as well as a schizophrenia candidate that could improve patients’ cognition.
You may also be interested in...
Deals Of The Week: Celgene/Acetylon, Cytomedix/Aldagen, Vernalis/Tris Pharma
CEOs from Sanofi and GlaxoSmithKline hold forth on how previous years’ preparations have led up to this moment, a post-patent-cliff future for big pharma.
Deals Of The Week: Amgen/Micromet, Celgene/Avila, Watson/Ascent
Along with three biotech acquisitions, the week in deal-making also saw the licensing of a new hepatitis C candidate with a different mechanism of action, further consolidation in the animal health field, and the end of Ipsen and Santhera’s collaboration on Alzheimer’s drug fipamezole.
The Existential Dilemma of Israeli Biotech
Israel's biotech industry -- a scientific and entrepreneurial dynamo but starved for capital, infrastructure, and managerial experience -- is facing its existential dilemma. For some, the industry's current problems are merely a reflection of economic Darwinism; others are planning more radical financing innovations. Meanwhile, the relatively rich in Israel, some of the incubators like Clal, and especially the country's biggest company, Teva, are soaking up the available opportunities for relatively little money.